Adlai Nortye (ANL)

• Market cap: $46.1M
• 1 day: -8.09%
• 5 days: -9.42%
• 1 month: -7.41%
• 3 months: -28.98%
• 6 months: -26.47%
• Year to date: -48.77%
• 1 year: -45.18%
• 5 years: -91.67%
• 10 years: -91.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Employees: 123